It is a pharma private limited company based in Indore, Madhya Pradesh, India, established in 2001.
2001 | Indore, Madhya Pradesh, India | ActiveBasil Drugs Private Limited, a active private limited company, was established on 16 April 2001 in Indore, Madhya Pradesh, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U24232MP2001PTC014624. Registered under ROC Roc Gwalior. it is unlisted. It has an authorized capital of ₹0.50 M and a paid-up capital of ₹0.50 M.
Formerly known as Basil Drugs Limited. It upholds a compliant status. Its leadership includes Rajesh Kumar Singh (Managing Director), Tara Kushwaha (Whole-Time Director), Mohammad Shakil Sheikh (Whole-Time Director). Past directors included Rajesh Kumar Singh, Manish Kumar Jain, Tara Kushwaha. It holds ₹0.68 M open charges and no settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at N- 60, Anoop Nagar, Indore, Madhya Pradesh, 452011.
U24232MP2001PTC014624
014624
16 April 2001
₹0.50 M
₹0.50 M
Roc Gwalior
Unlisted
Active
Explore comprehensive insights into Basil Drugs Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajesh Kumar Singh | Managing Director | 16 Apr 2001 | Current |
| Tara Kushwaha | Whole-Time Director | 16 Apr 2001 | Current |
| Mohammad Shakil Sheikh | Whole-Time Director | 30 Sep 2007 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 01 Oct 2013 | Past |
| Pramod Abcsdd | Director | 15 Apr 2010 | Past |
| Pramod Abcsdd | Director | 01 Oct 2013 | Past |
| Pramod Abcsdd | Director | 01 Oct 2013 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Basil Drugs Private Limited, for the financial year ended 2016, experienced modest growth in revenue, with a 4.8% increase. The company also saw a slight decrease in profitability, with a 5.95% decrease in profit. The company's net worth moved up by a moderate rise of 9.19%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2017, Basil Drugs had a promoter holding of 51.09% and a public holding of 48.91%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹683,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Aug 2018 | Others | ₹0.26 M | Open |
| 18 Dec 2015 | Icici Bank Limited | ₹0.23 M | Open |
| 17 Oct 2001 | State Bank Of Indore | ₹0.20 M | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Basil Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Basil Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Basil Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Basil Drugs Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.
The activity Basil Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Gwalior. was completed.
Progress on A charge with Others amounted to Rs. 0.26 M with Charge ID 100207896 was registered on 13 Aug 2018. was documented.
Progress on A charge with Icici Bank Limited amounted to Rs. 0.23 M with Charge ID 10620077 was registered on 18 Dec 2015. was documented.
The activity Mohammad Shakil Sheikh was appointed as a Whole-time director was appointed as a Whole-time director on 30 Sep 2007 & has been associated with this company since 18 years 2 months . was completed.
A charge with State Bank Of Indore of Rs. 0.20 M registered on 17 Oct 2001 with Charge ID 90203856 was modified on 10 Nov 2004. was recorded as a recent event.
The CIN of Basil Drugs Private Limited is U24232MP2001PTC014624.
Basil Drugs Private Limited is headquartered at N- 60, Anoop Nagar, Indore, Madhya Pradesh, 452011.
Basil Drugs Private Limited was incorporated on 16 April 2001.
The current directors of Basil Drugs Private Limited are
The primary industry of Basil Drugs Private Limited is Trade.
Basil Drugs Private Limited is unlisted.
The authorized capital of Basil Drugs Private Limited is ₹0.50 M, and the paid-up capital is ₹0.50 M.
The compliance status of Basil Drugs Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX